Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2023-02-10 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2023-02-10 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) providing an update on the company's manufacturing facility status with the US FDA. It references a previous letter and informs about an exception granted by the FDA to supply a specific drug despite an import alert. The letter states it is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically relates to material event disclosures. The document is short (1949 characters) and does not contain financial data, financial statements, or detailed report content. It is an announcement of a regulatory or compliance update rather than a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2023-01-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, AKYNZEO I.V., by Glenmark Pharmaceuticals in India. It is addressed to stock exchanges and includes a media release for immediate publication. The content focuses on product launch details, marketing rights, and company background. There are no financial statements, regulatory filings, voting results, or management discussions. The document is a corporate announcement about a product launch rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2023-01-23 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a notification addressed to stock exchanges regarding Glenmark Pharmaceuticals Ltd.'s divestment of select brands from its dermatology segment to another company. It includes details of the transaction, the strategic rationale, and company background. The document is short (3616 characters) and serves as an official announcement of a corporate transaction rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial analysis. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including divestments and asset sales.
2023-01-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is an invitation to an earnings call for Glenmark Pharmaceuticals Ltd. regarding their Q3 FY 2022-23 results. It includes details about the date, time, dial-in numbers, and contact information for clarifications. There is no actual financial data or detailed report content present, only an announcement of the call event. This matches the definition of a Call Transcript (CT) document type, but since this is an invitation and not the transcript itself, it is best classified as a Call Transcript (CT) because the invitation is directly related to the earnings call event. The document length is short and does not contain financial statements or analysis, so it is not an Interim Report or Earnings Release. Therefore, the best fit is Call Transcript (CT) with moderate to high confidence.
2023-01-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product (Sacubitril + Valsartan tablets) by Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release about the product launch, pricing, market data, and company background. There is no financial data, earnings information, regulatory filings, or management discussion. The content is promotional and informational about a product launch rather than a financial or regulatory report. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories, which is Regulatory Filings (RNS).
2023-01-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.